SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.96−0.12 (-3.90%)
Close on Nov 13, 2026Market cap $269.32MP/E –Yield –
SAB Biotherapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
SAB Biotherapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$81.97M. For fiscal 2025 it was -$45.96M. The highest annual figure on record is $20.94M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.96M | – |
| FY2024 | Dec 31, 2024 | -$38.20M | – |
| FY2023 | Dec 31, 2023 | -$34.42M | – |
| FY2022 | Dec 31, 2022 | -$25.75M | – |
| FY2021 | Dec 31, 2021 | -$11.90M | -156.9% |
| FY2020 | Dec 31, 2020 | $20.94M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.10M | – |
| Q2 FY2026 | Jun 30, 2026 | -$22.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.98M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.93M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.24M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.41M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.43M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.95M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.96M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.92M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.07M | -678.3% |
| Q4 FY2021 | Dec 31, 2021 | -$6.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.62M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.61M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.05M | – |
See a number that looks wrong?